We are live on ! Find out more
AMAM

Ambrx Biopharma Inc
AMAM

Delisted

AMAM was delisted on the 6th of March, 2024.

Back to rankings

16 hedge funds and large institutions have $152M invested in Ambrx Biopharma Inc in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

7% more funds holding

Funds holding: 15 → 16 (+1)

8% less capital invested

Capital invested by funds: $165M → $152M (-$13.4M)

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

Holders
16
Holders Change
+1
Holders Change %
+6.67%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
4
Reduced
5
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$22.9M
2
AG
Artal Group
Luxembourg
+$14.5M
3
SCM
Suvretta Capital Management
New York
+$11.8M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.08M
5
Renaissance Technologies
Renaissance Technologies
New York
+$132K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$480K
2
CCM
CAAS Capital Management
New York
-$301K
3
GCM
Ghisallo Capital Management
Massachusetts
-$203K
4
OCA
Octagon Capital Advisors
New York
-$147K
5
Fidelity Investments
Fidelity Investments
Massachusetts
-$13.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$34.8M -$13.4K -1,200 -0%
BlackRock
2
BlackRock
New York
$25.9M +$22.9M +2,049,265 +250%
CAM
3
Cormorant Asset Management
Massachusetts
$22.5M – – –
AG
4
Artal Group
Luxembourg
$19.4M +$14.5M +1,302,291 +153%
FI
5
Fosun International
China
$17.5M – – –
Adage Capital Partners
6
Adage Capital Partners
Massachusetts
$17.4M +$1.08M +96,408 +5%
SCM
7
Suvretta Capital Management
New York
$9.55M +$11.8M +1,057,735 New
OCA
8
Octagon Capital Advisors
New York
$3.04M -$147K -13,132 -4%
Millennium Management
9
Millennium Management
New York
$889K -$480K -43,012 -30%
Norges Bank
10
Norges Bank
Norway
$632K – – –
Tudor Investment Corp
11
Tudor Investment Corp
Connecticut
$182K – – –
CCM
12
CAAS Capital Management
New York
$118K -$301K -26,932 -67%
Renaissance Technologies
13
Renaissance Technologies
New York
$107K +$132K +11,800 New
Morgan Stanley
14
Morgan Stanley
New York
$25K – – –
MIFH
15
Migdal Insurance & Financial Holdings
Israel
$1K -$848 -76 -38%
Bank of America
16
Bank of America
North Carolina
$1K +$335 +30 +30%
GCM
17
Ghisallo Capital Management
Massachusetts
– -$203K -15,000 Closed

AMAM Hedge Fund Activity: Q4 2021 in Review

16 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in Ambrx Biopharma Inc (AMAM) for Q4 2021, worth a combined $152M — down 8.1% from $165M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new AMAM positions and 1 closed out — a net gain of 1 holder — while 4 added to existing stakes and 5 trimmed.

The largest buyer was BlackRock, adding an estimated $22.9M. The largest seller was Millennium Management, cutting an estimated $480K.

  • 16 institutional investors held Ambrx Biopharma Inc (AMAM) as of Q4 2021, up from 15 in Q3 2021.
  • Funds reported $152M of Ambrx Biopharma Inc stock for Q4 2021, down 8.1% quarter-over-quarter.
  • 2 funds opened new Ambrx Biopharma Inc positions in Q4 2021 and 1 closed out, a net change of +1 holder.
  • The largest Ambrx Biopharma Inc buyer in Q4 2021 was BlackRock, an estimated $22.9M added.
  • The largest Ambrx Biopharma Inc seller in Q4 2021 was Millennium Management, an estimated $480K sold.

Based on aggregated 13F filings for Q4 2021.